Moderna's new version of its COVID-19 vaccine, which targets two virus variants including Omicron, has outperformed the company's original Spikevax shot in a head-to-head clinical trial.
Moderna has joined forces with non-profit organisation IAVI on a third phase 1 trial of its candidate HIV vaccine in Africa, where the burden of the virus is still being keenly felt.
Administering a fourth dose of an mRNA COVID-19 vaccine provides a stronger level of protection than a third dose, particularly in the over-70s, according to the latest readout from the UK
Moderna has reported preliminary clinical results with a bivalent version of its COVID-19 vaccine that combines its original version with another targeting the Beta variant, and seems to of
It is too early to consider widespread use of a second COVID-19 vaccine booster dose, according to the European Centre for Disease Prevention and Control (ECDC) and EMA's COVID-19 task forc
Bavarian Nordic has licensed rights to its respiratory syncytial virus (RSV) vaccine in China and certain other Asian markets to Shanghai's Nuance Pharma in a $225 million deal.